Nasdaq GlobeNewswire

MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer

Del

Dr. Frédéric Sedel to Transition to CSO

PARIS, July 26, 2018 (GLOBE NEWSWIRE) -- MedDay, a pioneering pharmaceutical company focused on the treatment of nervous system disorders, today announces the appointment of Christian Chavy MBA as Chief Executive Officer, effective 27th August 2018.

Mr. Chavy will succeed Dr. Frédéric Sedel, CEO and Co-Founder of MedDay, who will remain in his existing role until August 27th.  Dr. Sedel will then transition to Chief Scientific Officer and continue to serve on the board of directors.

Commenting on the appointment, Catherine Moukheibir, Chairman of the board, said, "We are thrilled to have Christian take on the role of CEO at this critical time for MedDay as we execute on our confirmatory Phase III clinical trial of MD1003 in progressive MS and make preparations to become a commercial stage company." 

"On behalf of the Board of Directors, I would also like to thank Dr. Frédéric Sedel, our co-founder, who has been instrumental in building MedDay into the company that it is today and has laid the groundwork for a company that ultimately should bring innovative treatments for patients," continued Mrs. Moukheibir. "Under his leadership, MedDay has advanced our lead candidate MD1003 into late stage clinical development, including completion of a successful Phase III trial in progressive MS, and is building a pipeline of promising candidates to treat CNS diseases.  The appointment of Christian Chavy represents a continuation of this strategy. We look forward, also, to further contributions from Frédéric Sedel in his new role as Chief Scientific Officer."

Mr. Christian Chavy commented, "I am honored to be appointed CEO of MedDay.  MD1003, which has a novel mechanism of action and which has already demonstrated strong clinical activity, is positioned to transform the treatment paradigm for progressive multiple sclerosis. We look forward to completing the Phase III trial and see a clear path to approval in the major markets, including U.S. and EU. MedDay is also dedicated to finding effective treatments for severe diseases of the nervous system through our pioneering work of targeting brain metabolism."

Dr. Frédéric Sedel commented, "I am convinced that Christian Chavy has the right skill set and vision to bring MedDay to the next stage. I am very excited with my new role as company CSO which I believe is the area where I can create the most value."

Mr. Chavy is a highly accomplished pharmaceutical executive with experience in Europe and North America. Most recently, he was the CEO of Stallergenes (2014-2016) and Partner at Ares Life Sciences (2010-2014).  His career highlights include 9 years at Actelion Pharmaceuticals (2000-2009) where he was promoted to President of Global Operations, with responsibility over USA, Europe, Japan and rest of the world. Prior to joining Actelion, he was VP, Head of the reproductive health commercial unit at Serono in Geneva and Chairman of Serono's French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France.  Earlier in his career he held roles of increasing responsibility at Bristol-Myers France, SmithKline and French Laboratories, and Merck Sharpe & Dohme.

Mr. Chavy is currently chairman of the board of Ixaltis, a specialty pharmaceutical company developing innovative treatment for genitourinary tract disorders that he founded, and serves on the board of Cerenis. He is a graduate of the Ecole Supérieure des Sciences Economiques et Commerciales (ESSEC) and the Institut de Contrôle de Gestion (ICG).

About MedDay
MedDay is a pioneering pharmaceutical company targeting brain metabolism to treat nervous system disorders. The company was founded in 2011.  The lead product, MD1003 is a formulation of high dose Pharmaceutical grade Biotin (hdPB) developed for progressive multiple sclerosis and other demyelinating diseases. The R&D pipeline also includes MD1103 in autism spectrum disorders and MD1105 in Alzheimer's disease.

MedDay explores brain metabolic pathways through its metabolomics research platform, SPECMET, which supports the discovery of additional pipeline assets. SPECMET screens cerebrospinal fluid (CSF) from patients with various Central Nervous System (CNS) disorders to identify the disrupted metabolic pathways. Compounds that are known to affect these metabolic pathways are then identified and further developed. SPECMET was developed in collaboration with the Commissariat à l'Energie Atomique (CEA) and in March 2017, MedDay acquired the health division of Profilomic SA, an innovative company formed out of the CEA in 2010, which significantly strengthened MedDay's research capabilities as the company aims to expand its pipeline.

MedDay is well funded by investors including Sofinnova Partners, InnoBio, Andera Partners and Bpifrance Large Venture. MedDay is headquartered in Paris and has a team in Boston.

For more information, please see: www.medday-pharma.com. Follow us on Twitter: @MedDayPharm.

Contact information:
MedDay Pharmaceuticals
Email: contact@medday-pharma.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Meddday Pharmaceuticals via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

WillScot Announces Closing of Warrant Exchange Offer11.12.2018 22:05Pressemelding

BALTIMORE, Dec. 11, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced the closing of its previously announced exchange offer (the “Exchange Offer”) relating to certain outstanding warrants issued in 2015 (the “Warrants”). Under the terms of the Exchange Offer, each Warrant holder had the opportunity to receive 0.18182 shares of WillScot Class A Common Stock, par value $0.0001 per share (“Common Stock”), for each Warrant tendered by the holder and exchanged pursuant to the Exchange Offer. As of the closing of the Exchange Offer on December 11, 2018, 45,131,827 outstanding Warrants were properly tendered and not withdrawn in the Exchange Offer. 45,031,827 of the Warrants tendered were public warrants, representing approximately 89% of the public warrants, and approximately 100,000 Warrants tendered were private warrant

DoubleVerify and InMobi Unite to Combat Mobile App Fraud11.12.2018 18:02Pressemelding

Partnership brings mobile app fraud prevention to advertisers globally NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- DoubleVerify ("DV"), the leading independent provider of marketing measurement software and analytics, today announced a partnership with InMobi, a global provider of enterprise platforms for marketers. As part of the partnership, DoubleVerify will provide always-on fraud filtering and measurement for mobile in-app advertising campaigns across the InMobi Exchange globally. The integration with InMobi covers pre-bid targeting for all InMobi Exchange impressions within the leading mobile in-app platform, as well as monitoring of post-bid fraud activity, such as spoofing – enabling InMobi to continuously refine the quality of its mobile ad inventory. “DV’s partnership with InMobi demonstrates our commitment to provide consistent, comprehensive quality coverage for global brand advertisers,” said Matt McLaughlin, COO at DoubleVerify. “With ad spend increasingly concentrated in

Claroty Announces Major Enhancements to Market-Leading Industrial Cybersecurity Platform11.12.2018 15:00Pressemelding

Groundbreaking multispectral data acquisition and network segmentation capabilities provide deeper OT network visibility and reduce risk for industrial enterprises and critical infrastructure providers NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Claroty, the leader in operational technology (OT) network protection, today announced several significant enhancements to its award-winning Continuous Threat Detection product and technology integrations with several leading industrial automation, network infrastructure and cybersecurity providers. Already the industry’s most complete industrial control systems (ICS) cybersecurity platform, this release incorporates new functionality to provide even more “extreme” visibility into ICS networks and help industrial enterprises decrease the risk of a cyberattack. The latest release of Claroty Continuous Threat Detection provides a large number of significant enhancements including: Virtual Zones and OT Network Segmentation – an innovative approach

INN Launches Battery Metals Channel11.12.2018 15:00Pressemelding

The new battery metals channel is designed to educate investors with original content and expert insight on the growing battery metals industry. VANCOUVER, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Investing News Network (INN) announces the launch of its battery metals channel. Responding to the growth and evolution of the battery metals market, this channel will host news, educational content and expert opinions on the lithium, cobalt, graphite, vanadium and manganese market segments. “INN has been a trusted source of information on the lithium, cobalt, graphite, vanadium and manganese markets for nearly a decade, and is excited to bring these sectors together under the battery metals umbrella,” said Nick Smith, CEO and publisher at INN. “Through connections with experts, our leading team of experienced writers creates original, insightful content on battery metals. INN educates investors in the industry by providing information they may never have access to on their own,” S

Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer11.12.2018 14:30Pressemelding

KENSINGTON, Md. and SHORASHIM, Israel, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, announced the appointment of Hermann Russ, M.D., Ph.D., as its chief scientific officer, effective December 1, 2018. Dr. Russ invented the use of the company’s lead molecule GAL-101/MRZ-99030 for the treatment of degenerative diseases of the retina, including glaucoma and dry macular degeneration. He is also co-inventor of the so-called “trigger effect” of GAL-101/MRZ-99030 and GAL-102/MRZ 14042, which is a unique reverse prion-like self-propagation mechanism of action important for the company’s eye drop and oral treatment regimens. “We are gratified that Dr. Russ is joining the Galimedix management team, as his knowledge in the field, as well as intimate experience with the compound, have already proven instrumental in the development of our company to date,” commented Andrew Pearlman, Ph.D., CEO of Galimedix

Farmako: Cannabis distributor to become gateway to Europe11.12.2018 10:00Pressemelding

Company is first to apply for a licence in the United Kingdom AAA-Team pushes to become gateway to Europe Company first to apply for distribution licences in UK Support of Canadian LP to obtain EU-GMP Focus on research and development FRANKFURT, Germany, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The Frankfurt-based pharmaceutical company Farmako is a research-based pharmaceutical company that distributes medical cannabis. The company is active in all European markets that have created a legal basis for cannabinoid therapies. It is the first company for medical Cannabis pursue distribution licences in multiple European countries. Fort hat, it will rely on EU-GMP certified suppliers. The German market for medical cannabis is estimated at 19.1 million euros in 2018 and at 200 million Euros by 2019. For 2028, experts expect a market volume for medical cannabis of 7.8 billion euros in Germany, an increase by a factor of 400. The number of patients for cannabinoid therapies in Germany has grown from

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom